Aspirin also known as acetylsalicylic acid is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin also has an antiplatelet, or "anti-clotting", effect and is used in long-term, low doses to prevent heart attacks, strokes and blood clot formation in people at high risk for developing blood clots. It has also been established that low doses of aspirin may be given immediately after a heart attack to reduce the risk of another heart attack or of the death of cardiac tissue.
Screening pregnant women at 36 weeks using a validated risk model and offering risk-stratified planned early-term birth reduced the incidence of term pre-eclampsia by about 30 percent without increasing maternal or neonatal complications. The randomised PREVENT-PE trial demonstrates that a personalised timing-of-birth strategy can prevent term pre-eclampsia where no effective medical prevention currently exists.
Planned birth at term reduces the incidence of pre-eclampsia in women at high risk of the condition, without increasing emergency Caesarean or neonatal unit admission, according to new trial results.
Bird flu viruses are a particular threat to humans because they can replicate at temperatures higher than a typical fever, one of the body's ways of stopping viruses in their tracks, according to new research led by the universities of Cambridge and Glasgow.
Researchers at NYU and partners within the International Healthy Outcomes of Pregnancy for Everyone (HOPE) Consortium have developed a novel tool, the Preterm Birth Actionable Risk Index (PTB-ARIx), designed to identify pregnant individuals at high risk for having a preterm birth (PTB, or delivery before 37 weeks).
A minimally invasive heart procedure to correct irregular heart rhythms called catheter ablation may reduce the risk of stroke enough that some patients can discontinue blood thinners, according to a preliminary late-breaking science presentation today at the American Heart Association's Scientific Sessions 2025.
One year of treatment with either of two strong blood-thinning medications—ticagrelor and prasugrel—by people with type 1 or type 2 diabetes who had a drug-eluting stent placed in their heart to treat coronary artery blockages did not offer the same level of benefit to prevent stent clotting, heart attacks, and bleeding complications, according to findings presented during a preliminary late-breaking science session during the American Heart Association's Scientific Sessions 2025 in New Orleans on November 10.
One year of dual antiplatelet therapy with one of two potent P2Y12 inhibitors-ticagrelor or prasugrel-in people with Type 1 or Type 2 diabetes who had received a drug-eluting stent did not offer the same level of benefit at preventing stent clotting, heart attacks and bleeding complications, according to a preliminary late-breaking science presentation today at the American Heart Association's Scientific Sessions 2025.
New research from Intermountain Health in Salt Lake City finds that patients diagnosed with peripheral arterial disease (PAD) who also have atrial fibrillation (AFib) face a significantly higher risk of major adverse cardiovascular events (MACE).
People with Type 2 diabetes (T2D) and an elevated risk for cardiovascular disease (CVD) who took low-dose aspirin were less likely to experience a major cardiovascular event, including heart attack, stroke or death, than people with T2D at similar CVD risk who did not take low-dose aspirin, according to a preliminary study to be presented at the American Heart Association's Scientific Sessions 2025.
Some products of arachidonic acid have already been well studied: the prostanoids formed by cyclooxygenases are central mediators of inflammation, fever, and pain.
NSAID-exacerbated respiratory disease, N-ERD, is associated with measurable changes in concentrations of lipid mediators involved in inflammation and pain modulation, a new study shows.
Researchers at Baylor College of Medicine have developed a powerful new data analysis method named COOKIE-Pro (Covalent Occupancy Kinetic Enrichment via Proteomics) that provides a comprehensive, unbiased view of how a class of drugs, called covalent inhibitors, interacts with proteins throughout the cell.
Scientists at the NYU Pain Research Center have identified which receptor in prostaglandins-the hormone-like substance targeted by common painkillers-causes pain but not inflammation.
Obstetricians have long advised their pregnant patients that Tylenol is the safest option to reduce fever or pain. President Donald Trump stood before a national audience on Sept. 22 and contradicted that.
A Swedish-led research team at Karolinska Institutet and Karolinska University Hospital has shown in a new randomized clinical trial that a low dose of the well-known medicine aspirin halves the risk of recurrence after surgery in patients with colon and rectal cancer with a certain type of genetic alteration in the tumor.
A randomized placebo-controlled Finnish study showed that aspirin therapy does not provide significant relief for people suffering from chronic rhinosinusitis with nasal polyps who are hypersensitive to non-steroidal anti-inflammatory drugs (NSAIDs).
There was no benefit to modulating the intensity of antiplatelet therapy compared with standard antiplatelet therapy in high-risk patients who had undergone complex stenting procedures, according to late-breaking research presented in a Hot Line session today at ESC Congress 2025.
Noninferiority was not demonstrated for death and ischemic events between P2Y12 inhibitor monotherapy and dual antiplatelet therapy (DAPT) given for 12 months after stenting in patients with acute coronary syndromes (ACS), according to late-breaking research presented in a Hot Line session today at ESC Congress 2025 and simultaneously published in New England Journal of Medicine.
Dual antiplatelet therapy (DAPT) was not more effective than aspirin alone for the prevention of major adverse cardiovascular events and increased major bleeding in patients with acute coronary syndrome (ACS) who underwent coronary artery bypass grafting (CABG), according to late-breaking research presented in a Hot Line session today at ESC Congress 20251 and simultaneously published in New England Journal of Medicine.
Compared with crushed ticagrelor, intravenous cangrelor provided immediate, effective platelet inhibition, with no increase in major bleeding and lower mortality rates in patients with acute myocardial infarction and cardiogenic shock, according to late-breaking research presented in a Hot Line session today at ESC Congress 2025.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.